KR20240047964A - 항-csp 항체 - Google Patents

항-csp 항체 Download PDF

Info

Publication number
KR20240047964A
KR20240047964A KR1020247001320A KR20247001320A KR20240047964A KR 20240047964 A KR20240047964 A KR 20240047964A KR 1020247001320 A KR1020247001320 A KR 1020247001320A KR 20247001320 A KR20247001320 A KR 20247001320A KR 20240047964 A KR20240047964 A KR 20240047964A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001320A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 에릭 에머링
랜달 알. 케켐
숀 엠. 립파우
웨인 볼크머스
캐서린 엘. 윌리엄스
Original Assignee
아트레카, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트레카, 인크. filed Critical 아트레카, 인크.
Publication of KR20240047964A publication Critical patent/KR20240047964A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247001320A 2021-06-17 2022-06-16 항-csp 항체 Pending KR20240047964A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
US63/211,820 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Publications (1)

Publication Number Publication Date
KR20240047964A true KR20240047964A (ko) 2024-04-12

Family

ID=84526612

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001320A Pending KR20240047964A (ko) 2021-06-17 2022-06-16 항-csp 항체

Country Status (9)

Country Link
US (2) US11655290B2 (https=)
EP (1) EP4355774A4 (https=)
JP (1) JP2024524895A (https=)
KR (1) KR20240047964A (https=)
CN (1) CN117940450A (https=)
AU (2) AU2022292722B2 (https=)
IL (1) IL309422A (https=)
MX (1) MX2023014984A (https=)
WO (1) WO2022266383A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024214379A1 (en) * 2023-02-03 2025-08-21 Atreca, Inc. Anti-csp antibody variants
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN103732738A (zh) * 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
TW201708260A (zh) 2015-07-22 2017-03-01 優瑞卡醫療公司 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途
US11066464B2 (en) * 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US20220195023A1 (en) 2019-02-19 2022-06-23 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
EP4355774A4 (en) 2025-05-07
JP2024524895A (ja) 2024-07-09
US20230167169A1 (en) 2023-06-01
NZ806561A (en) 2025-06-27
US11655290B2 (en) 2023-05-23
CN117940450A (zh) 2024-04-26
IL309422A (en) 2024-02-01
US20230002483A1 (en) 2023-01-05
WO2022266383A1 (en) 2022-12-22
MX2023014984A (es) 2024-03-12
AU2025220692A1 (en) 2025-09-11
AU2022292722A1 (en) 2024-01-04
US12545723B2 (en) 2026-02-10
EP4355774A1 (en) 2024-04-24
AU2022292722B2 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
KR102414120B1 (ko) 인터류킨-21 뮤테인 및 치료 방법
KR101251157B1 (ko) Ｃｄ37-특이적 결합 분자 및 ｃｄ20-특이적 결합 분자를사용한 ｂ-세포 감소
DK2740744T3 (da) Sp35-antistoffer og anvendelser deraf
KR100927261B1 (ko) 결합 도메인-면역글로불린 융합 단백질
DK2536764T3 (en) ANTI-CD28 HUMANIZED ANTIBODIES
KR20200110358A (ko) 항-pd-1 항체 및 치료 방법
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20200135935A (ko) 유도 및 네비게이션 제어 단백질 및 이의 제조 및 사용 방법
CN111655728A9 (zh) 结合ctla-4的抗体及其用途
SG189772A1 (en) Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
KR20120111932A (ko) 항-인간 ｃｄ52 면역글루불린
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
JP2022530301A (ja) Ｃｄ３抗原結合性断片及びその使用
KR20130108430A (ko) 항-노치1 항체
CN110799537B (zh) 抗pd-1抗体及其制备和使用方法
CN115087673A (zh) 结合il4r的抗体及其用途
KR20240047964A (ko) 항-csp 항체
JP2023089273A (ja) 自己免疫疾患治療用抗体
CN114174536B (zh) 抗trem-1抗体及其用途
CN114144435B (zh) 针对人trem-1的抗体及其用途
CN101896502B (zh) 抗人TNFα单抗、分子进化及其应用
KR20230060531A (ko) Pd-1에 결합하는 항체 및 이의 용도
KR102955674B1 (ko) 신규한 결합 분자 및 이의 용도
WO2025194069A1 (en) Anti-csp antibody variants
OA21630A (en) Anti-CSP antibodies.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000